Comparison of Monoclonal Antibodies Aua1 and Ber Ep4 With Anti-Cea For Detecting Carcinoma Cells In Serous Effusions and Distinguishing Them From Mesothelial Cells

Commercially available monoclonal antibodies AUA1, BER EP4 and carcinoembryonic antigen (CEA) were applied to cell blocks from 95 serous effusions. AUA1 and BER EP4 were reactive with 89% of effusions known to contain carcinoma cells, and anti-CEA with 71%. They also reacted with cells in two effusions from patients with malignant disease which were regarded as negative on conventional cytological examination of Papanicolaou-stained smears. They were negative in all but one of the benign effusions. Using all three antibodies, 95% of effusions containing carcinoma cells were detected. Use of these antibodies could improve the cytological diagnosis of serous effusions.     

Identification of Malignant Cells In Serous Effusions Using A Panel of Monoclonal Antibodies Ber-Ep4, Mca-B-12 and Ema

A panel of three monoclonal antibodies (MoAbs) was tested on 29 benign and 53 malignant effusions with the aim of investigating its usefulness for the discrimination between benign and malignant lesions. The panel consisted of MoAbs directed against epithelial membrane antigen (EMA); MCA-b-12, reacting with a 350 kD glycoprotein with mucin-like characteristics present on human breast cancer cells and various other normal and neoplastic tissues, and Ber-EP4, directed against a 34 and 39 kD glycopeptide on human epithelial cells but not on mesothelium. Fifty-two (98%) of the malignant effusions reacted with EMA, 49 (92%) with MCA-b-12 and 44 (83%) with Ber-EP4. Fourteen per cent of benign effusions reacted with EMA, 17% with MCA-b-12 and 7% with Ber-EP4. All seven effusions obtained from patients with a malignant mesothelioma reacted with EMA, six of the seven cases staining intensively. None of the seven stained with Ber-EP4. MCA-b-12 did not react with the cells in one case of malignant mesothelioma. The results suggest that the combination of EMA and Ber-EP4 may be used to discriminate between benign and malignant cells and possibly also between adenocarcinoma and malignant mesothelioma. MCA-b-12 followed in general the reaction pattern of EMA, although often with a less intense staining reaction, making this antibody unsuitable for inclusion in the panel.     

Expression of Vimentin and Epidermal Growth Factor Receptor In Effusions From Patients With Breast Cancer; Correlation With Oestrogen and Progesterone Receptor Status

The epidermal growth factor receptor (EGFr) status and the vimentin (V) status of malignant cells in pleural fluids from patients with breast cancer were determined using an immunoperoxidase labelling technique. the results were correlated with the oestrogen receptor (ER) and the progesterone receptor (PR) status of the primary tumour and with disease-free survival time of the patient. A negative correlation between EGFr and V status and hormone receptor status was found. the longest mean survival time occurred in patients with negative EGFr and V status and positive hormone receptor (ER and PR) status. the shortest mean survival time occurred in patients with positive EGFr and V and negative ER and PR status. Le récepteur du facteur de croissance de l'epiderme (EGFr) et la vimentine (V) ont étéétudiées par une technique d'immunopéroxydase, au niveau des cellules malignes des épanchements pleuraux de malades traités pour cancer du sein. Les résultats ont été corrélés avec les récepteurs d'oestrogènes (ER) et de progestérone (PR) et avec la durée de survie sans récidive. Une corrélation négative est trouvée entre le récepteur de l'EGF, la vimentine et le taux des récepteur hormonaux. La survie moyenne la plus longue est observée chez des patientes négatives pour le récepteur de l'EGF et pour la vimentine et positives pour les récepteurs hormonaux (ER et PR). La plus courte survie est associée a la positivité du récepteur de l'EGF et de la vimentine et à la négativité de ER et PR. In Pleuraergüssen von Patientinnen mit Mammakarzinom wurden der Rezeptor für den epidermalen Wachstums-faktor (EGF) sowie Vimentin mit der Immunperoxydase- Technik untersucht. Die Ergebnisse wurden mit dem Vorliegen von Östrogen- und Progesteronrezeptoren im Tumor sowie dem rezidivfreien Intervall der Patientinnen korreliert. Eine negative Korrelation bestand zwischen EGF-Rezeptor und Vimentin. Die längste durchschnittliche Überlebenszeit wurde dagegen bei Patientinnen mit negativem Ergebnis für den EGF-Rezeptor und Vimentin jedoch positiven Hormonrezeptoren gefunden. Die kürzeste überlebenszeit lag bei Patientinnen mit positivem Rezeptor- und Vimentinnachweis und Fehlen der Hormonrezeptoren vor.     

Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V,caspase cleavage and dUTP incorporation assays

H. P. Dong, A. Holth, M. G. Ruud, E. Emilsen, B. Risberg and B. Davidson Measurement of apoptosis in cytological specimens by flow cytometry: comparison of annexin V, caspase cleavage and dUTP incorporation assays Objective: To compare the performance of different assays for measuring apoptosis in cytological specimens. Methods: Apoptosis was assessed in 27 specimens (22 effusions, five fine needle aspirates; 20 malignant, seven reactive) using flow cytometry, applying assays for the measurement of annexin V expression, caspase‐3 and ‐8 cleavage and deoxynucleotidyl transferase deoxyuridine triphosphates (dUTP) incorporation. Results were studied for differences between reactive and malignant specimens, as well as performance across assays. Results: Wide variation in the degree of apoptosis was observed in both benign and malignant specimens using all assays. However, the percentage of annexin V‐positive cells was higher compared with those showing caspase cleavage or dUTP incorporation in the majority of cases, irrespective of specimen type. Comparative analysis of benign and malignant specimens showed no significant differences in expression of any of the studied parameters. However, tumour cells and reactive mesothelial cells in pleural effusions had a significantly lower level of dUTP incorporation compared with their counterparts in peritoneal specimens (P = 0.001). Conclusions: The present data are in agreement with our previous observation in ovarian carcinoma effusions, that measurement of apoptosis by the annexin V assay provides higher expression values than those obtained by other assays, suggesting that this assay does not accurately reflect the degree of apoptosis in benign or malignant cells in effusions.     

EM-3通过Stat3通路诱导鼻咽癌细胞凋亡和G_2/M期阻滞并降低SP细胞比例

目的:研究白花地胆草(Elephantopus mollis H.B.K)的乙醇提取物EM-3抗肿瘤作用分子机制。方法:MTT、克隆形成抑制和细胞划痕实验检测EM-3对鼻咽癌细胞增殖、迁移能力的影响;Annexin V-FITC/PI双染法检测细胞凋亡;PI单染检测细胞周期;超速流式分选细胞仪检测鼻咽癌CNE2-S18肿瘤干细胞样SP细胞(side population cell)比例;Western blotting检测细胞凋亡、周期、侵袭迁移及肿瘤干细胞相关蛋白表达变化。结果:MTT、克隆形成抑制和细胞划痕实验结果表明,EM-3可以显著抑制鼻咽癌细胞的增殖,随着药物浓度的增大,细胞克隆数逐渐减少,体积逐渐变小,而且能够显著抑制鼻咽癌细胞的迁移;流式细胞术结果表明随着药物浓度的增加,凋亡率逐渐增加,并且G_2/M期细胞比例逐渐增加;超速流式分选细胞仪结果表明,EM-3可以显著降低CNE2-S18肿瘤干细胞样SP细胞的比例;Western blotting结果表明,随着药物浓度的增加,x IAP、Bcl-2、Cyclin D1、MMP2(药物高浓度)、MMP9、p-Met、Oct4(药物高浓度)及Sox2蛋白表达减少,而Cyclin B1、Bax蛋白表达增多,并伴随Caspase-9、Caspase-3活化及多聚ADP核糖聚合酶PARP酶切失活。结论:EM-3通过抑制Stat3通路诱导鼻咽癌细胞发生凋亡,并诱导G_2/M期阻滞。此外,EM-3经MMPs途径抑制鼻咽癌细胞迁移,同时可以有效降低CNE2-S18肿瘤干细胞样SP细胞干性。